AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9571510 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency ultrasound treatment, started immediately after plaster removal
Number of subjects: 38
Study 9571510 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ultrasound treatment)
Number of subjects: 38
Study 8150641 — intervention group
Group type: EXPERIMENTAL
Intervention: Music and muscle relaxation interventions (two or three 30-minute sessions of audiotape interventions with light classical music and verbal instructions for muscle relaxation)
Number of subjects: 56
Study 8150641 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 56
Study 2834976 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg acebutolol 5 min after induction of anesthesia
Number of subjects: 20
Study 2834976 — intervention group
Group type: COMPARATOR
Intervention: Control group without acebutolol treatment
Number of subjects: 20
Study 31904246 — intervention group
Group type: EXPERIMENTAL
Intervention: Water flosser + oscillating‐rotating powered toothbrush (WF)
Number of subjects: 70
Study 31904246 — intervention group
Group type: COMPARATOR
Intervention: Oscillating‐rotating powered toothbrush only (OR)
Number of subjects: 70
Study 30841946 — intervention group
Group type: EXPERIMENTAL
Intervention: Small for gestational age (SGA)
Number of subjects: 1208
Study 30841946 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal stunting at 1 year
Number of subjects: 1208
Study 30841946 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal stunting at 2 years
Number of subjects: 1208
Study 28104641 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanner 1 CT/CTA
Number of subjects: 52
Study 28104641 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanner 2 CT/CTA
Number of subjects: 52
Study 28104641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative peak skin dose from multiple CT/CTA scans
Number of subjects: 52
Study 28104641 — intervention group
Group type: COMPARATOR
Intervention: Volumetric CT dose index
Number of subjects: 52
Study 26414587 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ginger for the first three days of the chemotherapy cycle (n = 30)
Number of subjects: 60
Study 26414587 — intervention group
Group type: COMPARATOR
Intervention: Standard antiemetic treatment only (Control group, n = 30)
Number of subjects: 60
Study 26414587 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (n = 60)
Number of subjects: 60
Study 24145626 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior conjunctival autograft (CAU)
Number of subjects: 60
Study 24145626 — intervention group
Group type: COMPARATOR
Intervention: Inferior conjunctival autograft (CAU)
Number of subjects: 60
Study 21703071 — intervention group
Group type: COMPARATOR
Intervention: Control group (no saliva contamination)
Number of subjects: 80
Study 21703071 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva contamination with 1‐second air‐thinning
Number of subjects: 80
Study 21703071 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva contamination with 10 seconds of air‐drying
Number of subjects: 80
Study 21703071 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva contamination with reconditioning
Number of subjects: 80
Study 19627223 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based intervention (on-site counseling session and six telephone counseling sessions over a 3-month period)
Number of subjects: 41
Study 19627223 — intervention group
Group type: COMPARATOR
Intervention: Control group (health information brochures, a list of community resources, and a monthly telephone call to confirm contact information)
Number of subjects: 41
Study 16680254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg IV at surgical skin closure
Number of subjects: 60
Study 16680254 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 5 mg IV immediately after anesthesia induction
Number of subjects: 60
Study 16680254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg IV
Number of subjects: 60
Study 16680254 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 5 mg IV
Number of subjects: 60
Study 15590442 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy plus IVIG (500 mg/kg)
Number of subjects: 112
Study 15590442 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy alone (control group)
Number of subjects: 112
Study 12972104 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-80 mg)
Number of subjects: 16495
Study 12972104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16495
Study 12972104 — intervention group
Group type: COMPARATOR
Intervention: Other statins
Number of subjects: 16495
Study 12972104 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 16495
Study 11185637 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg
Number of subjects: 207
Study 11185637 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 207
Study 11185637 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 120 mg
Number of subjects: 207
Study 11185637 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 207
Study 11185637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 8874689 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for resident physicians (two one‐hour sessions with specially prepared printed materials)
Number of subjects: 384
Study 8874689 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompting intervention (fingerstick blood cholesterol determination prior to the patient's clinic visit)
Number of subjects: 384
Study 8874689 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both interventions
Number of subjects: 384
Study 8874689 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 384
Study 1425897 — intervention group
Group type: EXPERIMENTAL
Intervention: IV injection of soluble salts of acetylsalicylic acid
Number of subjects: 20
Study 1425897 — intervention group
Group type: EXPERIMENTAL
Intervention: IV injection of indomethacin
Number of subjects: 20
Study 1425897 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of indomethacin
Number of subjects: 20
Study 1425897 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen
Number of subjects: 20
Study 1425897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3887159 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol for two weeks before surgery and throughout the first postoperative week
Number of subjects: 14
Study 3887159 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care
Number of subjects: 14
Study 30265350 — intervention group
Group type: EXPERIMENTAL
Intervention: Manganese oxide (MnO) at 100 mg/kg
Number of subjects: 1080
Study 30265350 — intervention group
Group type: EXPERIMENTAL
Intervention: Manganese oxide (MnO) at 50 mg/kg
Number of subjects: 1080
Study 30265350 — intervention group
Group type: EXPERIMENTAL
Intervention: Manganese oxide (MnO) at 10 mg/kg
Number of subjects: 1080
Study 30265350 — intervention group
Group type: EXPERIMENTAL
Intervention: Manganese nanoparticles (NP‐Mn2O3) at 100 mg/kg
Number of subjects: 1080
Study 30265350 — intervention group
Group type: EXPERIMENTAL
Intervention: Manganese nanoparticles (NP‐Mn2O3) at 50 mg/kg
Number of subjects: 1080
Study 30265350 — intervention group
Group type: EXPERIMENTAL
Intervention: Manganese nanoparticles (NP‐Mn2O3) at 10 mg/kg
Number of subjects: 1080
Study 30265350 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of Mn supplementation from 100 mg/kg to 50 or 10 mg/kg
Number of subjects: 1080
Study 30265350 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of Mn supplementation
Number of subjects: 1080
Study 29628593 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg diluted in 20 mL normal saline (NS) over 10 min
Number of subjects: 90
Study 29628593 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 1.5 mg/kg diluted in 20 mL normal saline (NS) over 10 min
Number of subjects: 90
Study 29628593 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) infusion of 20 mL over 10 min (Control Group)
Number of subjects: 90
Study 26661403 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 600 mg/m2, day 1, every 3 weeks)
Number of subjects: 1055
Study 26661403 — intervention group
Group type: COMPARATOR
Intervention: EP (epirubicin 90 mg/m2 and paclitaxel 175 mg/m2, day 1, every 3 weeks)
Number of subjects: 1055
Study 26661403 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC
Number of subjects: 1055
Study 26661403 — intervention group
Group type: COMPARATOR
Intervention: EP
Number of subjects: 1055
Study 24767956 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music
Number of subjects: 23
Study 24767956 — intervention group
Group type: COMPARATOR
Intervention: Silence (control)
Number of subjects: 23
Study 22466101 — intervention group
Group type: EXPERIMENTAL
Intervention: Punctal occlusion with silicone plugs
Number of subjects: 30
Study 22466101 — intervention group
Group type: COMPARATOR
Intervention: Non-preserved artificial tears
Number of subjects: 30
Study 20168193 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing based on the stages of change (MISC) intervention, 3 interventions (1 in person, 2 on the phone).
Number of subjects: 30
Study 20168193 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 30
Study 18339797 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% feedback
Number of subjects: 40
Study 18339797 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced (62% faded) feedback
Number of subjects: 40
Study 16137355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac arrest group
Number of subjects: 121
Study 16137355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac arrest group (duration >10 min)
Number of subjects: 121
Study 16137355 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study 16137355 — intervention group
Group type: COMPARATOR
Intervention: AMI group
Number of subjects: 121
Study 12787260 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nefopam (20 mg)
Number of subjects: 24
Study 10803490 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem-based treatment strategy
Number of subjects: 10896
Study 10803490 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment strategy (diuretics or beta-adrenergic blockers)
Number of subjects: 10896
Study 7546987 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term oral anticoagulant treatment
Number of subjects: 3404
Study 1708859 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 21
Study 1708859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 6948541 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual patient education
Number of subjects: 39
Study 6948541 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education
Number of subjects: 39
Study 6948541 — intervention group
Group type: EXPERIMENTAL
Intervention: Written material only
Number of subjects: 39
Study 6948541 — intervention group
Group type: COMPARATOR
Intervention: All education groups
Number of subjects: 39
Study 31048181 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape byproduct (0; 100; 200; and 300 g/kg DM)
Number of subjects: 34
Study 31048181 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape byproduct (300 g/kg DM)
Number of subjects: 34
Study 31048181 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape byproduct inclusion
Number of subjects: 34
Study 27854065 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text message reminders for the first 2 weeks, then once weekly thereafter for 3 months.
Number of subjects: 24
Study 26062689 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (GDT) targeting stroke volume variation with an arterial pulse contour cardiac output monitor
Number of subjects: 40
Study 26062689 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (GDT)
Number of subjects: 40
Study 26062689 — intervention group
Group type: COMPARATOR
Intervention: Control group (fluid therapy at the discretion of the attending anesthesiologist)
Number of subjects: 40
Study 25276732 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention (phone calls from peers from the last three months of pregnancy until two months after delivery)
Number of subjects: 100
Study 25276732 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 100
Study 25276732 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 100
Study 22248554 — intervention group
Group type: EXPERIMENTAL
Intervention: Front-only suspension (FS)
Number of subjects: 7
Study 22248554 — intervention group
Group type: COMPARATOR
Intervention: Front-and-rear suspension (FRS)
Number of subjects: 7
Study 19704107 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-based therapy
Number of subjects: 259
Study 19704107 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based therapy
Number of subjects: 259
Study 16717477 — intervention group
Group type: COMPARATOR
Intervention: Itopride hydrochloride
Number of subjects: 0
Study 15595376 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexical form class cues suggestive of adjectives (Experiment 1)
Number of subjects: 112
Study 15595376 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexical form class cues suggestive of count nouns (Experiment 2)
Number of subjects: 112
Study 11246536 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (75 mg daily)
Number of subjects: 0
Study 11246536 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (additional treatment for three months)
Number of subjects: 0
Study 11246536 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with total cholesterol > 5.2 mmol/L taking low-dose aspirin)
Number of subjects: 0
Study 9728805 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (specific regimen not detailed), evaluated at baseline, 7 days, 14 days, and 25 days post-treatment.
Number of subjects: 17
Study 9728805 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment values of Hb < or = 9 g/dl in leukemia patients.
Number of subjects: 17
Study 9728805 — intervention group
Group type: COMPARATOR
Intervention: Control group of 12 healthy age-matched subjects.
Number of subjects: 17
Study 7995007 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg)
Number of subjects: 8
Study 7995007 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg)
Number of subjects: 8
Study 7995007 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril during angiotensin II infusion
Number of subjects: 8
Study 7995007 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril during angiotensin II infusion
Number of subjects: 8
Study 2660541 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 38
Study 2660541 — intervention group
Group type: COMPARATOR
Intervention: Arthrography
Number of subjects: 38
Study 2660541 — intervention group
Group type: COMPARATOR
Intervention: Sonography
Number of subjects: 38
Study 5356549 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent infusion of amino-acids and hormones (secretin and pancreozymin)
Number of subjects: 2
Study 5356549 — intervention group
Group type: COMPARATOR
Intervention: Administration of amino-acids or hormones individually
Number of subjects: 2
Study 86003 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-strength milk
Number of subjects: 46
Study 86003 — intervention group
Group type: COMPARATOR
Intervention: Clear fluids until diarrhoea settled, then full-strength milk reintroduced gradually in quarter-strength steps
Number of subjects: 46
Study 86003 — intervention group
Group type: COMPARATOR
Intervention: Clear fluids until diarrhoea settled, then full-strength milk reintroduced immediately
Number of subjects: 46
Study 31838217 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV)
Number of subjects: 1200
Study 31838217 — intervention group
Group type: COMPARATOR
Intervention: Trivalent influenza vaccine (TIV)
Number of subjects: 1200
Study 31838217 — intervention group
Group type: EXPERIMENTAL
Intervention: Both QIV and TIV
Number of subjects: 1200
Study 30947385 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral healthcare motivation intervention group
Number of subjects: 60
Study 30947385 — intervention group
Group type: COMPARATOR
Intervention: Control group (no advice)
Number of subjects: 60
Study 28958435 — intervention group
Group type: EXPERIMENTAL
Intervention: PSS without lumbar support
Number of subjects: 34
Study 28958435 — intervention group
Group type: EXPERIMENTAL
Intervention: PSS with lumbar support
Number of subjects: 34
Study 27884849 — intervention group
Group type: EXPERIMENTAL
Intervention: Fistula-based strategy (intervention)
Number of subjects: 100
Study 27884849 — intervention group
Group type: COMPARATOR
Intervention: Catheter-based strategy (control)
Number of subjects: 100
Study 24433434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (doses ranging from 0.3 to 10 mg/kg)
Number of subjects: 499
Study 24433434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 499
Study 23108147 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic index diet
Number of subjects: 185
Study 23108147 — intervention group
Group type: COMPARATOR
Intervention: Low glycemic index diet
Number of subjects: 185
Study 19539427 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GPT) or Pregabalin (PGB)
Number of subjects: 2422
Study 19539427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2422
Study 18377458 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter closure (ASO)
Number of subjects: 162
Study 18377458 — intervention group
Group type: COMPARATOR
Intervention: Surgical closure (SUR)
Number of subjects: 162
Study 12671693 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (initial dose 150 IU kg(‐1) three times weekly)
Number of subjects: 262
Study 12671693 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 262
Study 10872533 — intervention group
Group type: EXPERIMENTAL
Intervention: Total carbohydrate intake (% of energy)
Number of subjects: 2084
Study 10872533 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato carbohydrates (g)
Number of subjects: 2084
Study 10872533 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable carbohydrates (g)
Number of subjects: 2084
Study 10872533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal carbohydrates (g)
Number of subjects: 2084
Study 10872533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit carbohydrates (g)
Number of subjects: 2084
Study 10872533 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk carbohydrates (g)
Number of subjects: 2084
Study 8887822 — intervention group
Group type: EXPERIMENTAL
Intervention: HiEH/harassed
Number of subjects: 57
Study 8887822 — intervention group
Group type: EXPERIMENTAL
Intervention: HiNH/harassed
Number of subjects: 57
Study 8887822 — intervention group
Group type: COMPARATOR
Intervention: HiEH/nonharassed
Number of subjects: 57
Study 8887822 — intervention group
Group type: COMPARATOR
Intervention: LoEH
Number of subjects: 57
Study 8887822 — intervention group
Group type: COMPARATOR
Intervention: HiNH/nonharassed
Number of subjects: 57
Study 8887822 — intervention group
Group type: COMPARATOR
Intervention: LoNH
Number of subjects: 57
Study 1402013 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib‐CPS‐T
Number of subjects: 40
Study 1402013 — intervention group
Group type: COMPARATOR
Intervention: Hib‐CPS
Number of subjects: 40
Study 3987788 — intervention group
Group type: COMPARATOR
Intervention: Procyclidine (10 mg) - intravenous administration
Number of subjects: 6
Study 3987788 — intervention group
Group type: COMPARATOR
Intervention: Procyclidine (10 mg) - oral administration
Number of subjects: 6
Study 3987788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31571412 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg orally every 6 hours for 7 days
Number of subjects: 35
Study 31571412 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg
Number of subjects: 35
Study 28731373 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus 1% Metformin Gel (MF)
Number of subjects: 70
Study 28731373 — intervention group
Group type: COMPARATOR
Intervention: SRP plus placebo
Number of subjects: 70
Study 25616607 — intervention group
Group type: EXPERIMENTAL
Intervention: Active azithromycin (1 g) + placebo doxycycline
Number of subjects: 490
Study 25616607 — intervention group
Group type: EXPERIMENTAL
Intervention: Active doxycycline (100 mg twice a day ×7 days) + placebo azithromycin
Number of subjects: 490
Study 25616607 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg ×7 days)
Number of subjects: 490
Study 25616607 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse therapy (active doxycycline if first treated with active azithromycin)
Number of subjects: 490
Study 25616607 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse therapy (active azithromycin if first treated with active doxycycline)
Number of subjects: 490
Study 23827814 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training (fmθ uptraining)
Number of subjects: 32
Study 23827814 — intervention group
Group type: COMPARATOR
Intervention: Sham-neurofeedback training
Number of subjects: 32
Study 21831714 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical monitoring alone (CLIN)
Number of subjects: 493
Study 21831714 — intervention group
Group type: COMPARATOR
Intervention: Laboratory and clinical monitoring (LAB)
Number of subjects: 493
Study 19728275 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg bromazepam
Number of subjects: 39
Study 19728275 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg bromazepam
Number of subjects: 39
Study 19728275 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 39
Study 17362252 — intervention group
Group type: EXPERIMENTAL
Intervention: Pru p 3 sensitization in peach-allergic patients
Number of subjects: 30
Study 17362252 — intervention group
Group type: EXPERIMENTAL
Intervention: Profilin and Bet v 1 sensitization
Number of subjects: 30